Phase 4 N=20 Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding
Hypofibrinogenemia · Bleeding
Primary: Total Number of RBCs Used Over Admission — 5.8; 6.7 RBC Units
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=200 Novel Biomarkers of Thrombotic Risk
Myocardial Infarction
Primary: Cardiovascular Event - Myocardial Infarction, Stroke, Death — 17; 6 Participants — p=0.007
N/A N=1,260,576 Improving Anticoagulation Control in VISN 1
Anticoagulants · Atrial Fibrillation · Venous Thromboembolism
Primary: Percent Change in Time in Therapeutic Range (TTR) — 2.8; 0.5 percent change — p=<0.001
N/A N=50 The Clinical Utility of Thrombelastography in Guiding Prophylaxis of Venous Thromboembolism Following Trauma
Venous Thromboembolism
Primary: Hypercoagulability — 16; 18 participants
N/A N=99 Platelet Function in Resuscitated Patients
Acute ST Segment Elevation Myocardial Infarction
Primary: Platelet Inhibition Measured With Optical Aggregometry — 109; 253.8 AU*min
N/A N=246 Platelet Activity in Vascular Surgery and Cardiovascular Events
Cardiovascular Disease · Peripheral Artery Disease · Critical Limb Ischemia
Primary: Number of Patients in Which Platelet Activity Measurements Were Associated With Short-term Cardiovascular Events — 31; 16 participants
Phase 4 N=17 Use of Topical Tranexamic Acid and Bacitracin in Dialysis Patients
Arteriovenous Fistula
Primary: Clotting TIme — 6; 8 minutes
N/A N=400 Investigation of Clot in Ischemic Stroke and Hematoma Evacuation
Ischemic Stroke · Intracranial Hematoma
Primary: Clot Specimen Histology — 373; 12 Count of specimen
N/A N=100 Safety Study of Quickclot for Bleeding Control After Adenotonsillectomy
Sleep Apnea, Obstructive
Primary: Total Suction Electrocautery Time Required for Hemostasis Will be Recorded as Seconds — 155.3; 60.9; 94.5 seconds
Phase 3 N=57 Does Plasma Reduce Bleeding in Patients Undergoing Invasive Procedures
Blood Coagulation Disorders · Hemorrhage
Primary: Change in Hemoglobin Level — -0.6; -0.4 g/dL
N/A N=266,890 The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders: a United Kingdom (UK) Matched Cohort Study
Venous Thromboses · Venous Thromboembolism · Deep Vein Thrombosis
Primary: Risk of Venous Thromboembolism (VTE) — 335; 845; 132; 3804 Participants
N/A N=24 Coagulation Factor Changes Associated With Postpartum Hysterectomies
Obstetric Labor Complications · Hemorrhage · Complications; Cesarean Section
Primary: Fibrinogen Level at 2 Hours After Delivery — 186; 418 mg/dL — p=<0.05
Phase 3 N=465 Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care
COVID-19
Primary: Composite Outcome of ICU Admission, Non-invasive Positive Pressure Ventilation, Invasive Mechanical Ventilation, or All-cause Death up to 28 Days. — 37; 52 Participants
N/A N=68 Comparison of Blood Product Use and Bleeding Events During and After Endoscopic or Neurosurgical Procedures in Patients With Cirrhosis and Coagulopathy
Cirrhosis · Coagulopathy
Primary: Intra-operative Blood Loss — 2000; 3000 milliliters
Phase 3 N=52 Use of a Novel Fibrin Sealant in Total Knee Arthroplasty
Osteoarthritis · Intraoperative Bleeding
Primary: Primary--Percent Change of Pre- to Post-Operative Hemoglobin — 20.1; 22.5 Percent Change — p=0.2
Phase 3 N=209 Immunogenicity and Safety Study of Topical Recombinant Thrombin in Surgical Hemostasis
Spinal Surgery · Vascular Surgery
Primary: Number of Participants With Anti-recombinant Thrombin (rThrombin) Product Antibodies at Day 29 in Participants With and Without Anti-bovine Thrombin Product Antibodies…
N/A N=51 Thromboelastography-derived Functional Fibrinogen Levels
Focus of Study · Coagulation Status of Cardiac Surgery Patient · Reducing Excess Blood Transfusion
Primary: Change in Thromboelastography-derived Functional Fibrinogen Level (FLEV) — -1.1 mg/dL
N/A N=324 Prospective, Multicenter, Multidisciplinary, Controlled Clinical Investigation Evaluating the Safety and Efficacy of PerClot® Polysaccharide Hemostatic System
Blood Loss, Surgical
Primary: Number of Participants With Achievement of Hemostasis at 7 Minutes — 145; 149 Participants — p=0.005
N/A N=52 Hemosonics- VCU Cardiac Surgery Clinical Study
Cardiopulmonary Bypass
Primary: Clot Time — 4.9; 3.3 min — p=<0.001
N/A N=60 A New Approach for Controlling Hemostasis During Canal Treatment
Blood Contamination of Root Canal During Endodontic Therapy
Primary: Change From Baseline in Root Canal Bleeding — 3.40; 3.73; 0.26; 3.03 millimeters — p=<.0001
N/A N=100 The Effect of the Hemobag® Ultrafiltration System on Blood Conservation and Coagulation After Cardiopulmonary Bypass
Blood Coagulation Disorders
Primary: Amount of Chest Catheter Drainage 24 Hours Postoperatively — 766; 626 mL
Phase 2 N=181 Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemostasis During Surgery
Hemostasis
Primary: Proportion of Subjects Achieving Hemostasis by Five Minutes After Treatment Start at the TBS — 75.0; 75.0; 73.9; 82.5 percent of subjects achieving hemostasis
N/A N=15 Identifying the Anti-Blood-Clotting Compounds in Garlic
Arteriosclerosis · Intracranial Arteriosclerosis
Primary: Percent Platelet Aggregation — 71.4; 72.5 percent platelet aggregation
N/A N=25 Tranexamic Acid and Blood Clots in Knee Surgery
Venous Thrombosis
Primary: Deep Vein Thrombosis — 2 Participants
N/A N=70 Femoral Vein Hemostasis After Ablation for Atrial Fibrillation With Manual Pressure Versus a Figure of 8 Suture
Atrial Fibrillation
Primary: Time Required to Achieve Hemostasis — 0; 15 minutes
Phase 1 N=24 Thrombosomes® in Bleeding Thrombocytopenic Patients
Thrombocytopenia · Hematologic Diseases · Bone Marrow Aplasia
Primary: Number of Patients With Treatment-Emergent Adverse Events (TEAE) — 7; 6; 5 Participants
Phase 2 N=15 A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII Deficiency
Factor XIII Deficiency
Primary: Peak FXIII Concentration at Steady State — 0.9 Units/mL
Phase 4 N=98 Clopidogrel Monotherapy in Patients With High Bleeding Risk
Bleeding Complications
Primary: Ischemic Risk Post-PCI in High Bleed Risk Patients With Genotype-guided Single Antiplatelet Therapy — 0; 1 Participants
N/A N=355 Hemostasis With QuikClot® Radial® Pad Versus TR Band® After Transradial Artery Access
Coronary Artery Disease
Primary: Initial Successful Hemostasis — 85; 88; 51; 74 Participants — p=0.906
Phase 4 N=390 Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial
COVID-19 · Venous Thromboembolism · Arterial Thrombosis
Primary: Venous or Arterial Thrombotic Events: Full-dose Anticoagulation Versus Standard-dose Prophylactic Anticoagulation — 4,486; 2,351 Number of wins — p=0.028